An article in Globe Newswire described dermatomyositis (DM) as a rare disease that involves a unique skin rash and muscle weakness. Currently doctors are relying on traditional disease-modifying anti-rheumatic drugs…
In some cases, dermatomyositis can be difficult to treat. A variety of treatment options are available, from corticosteroids and immunosuppressants to antimalarials, colchicine, alendronate, and warfarin. But this rare condition…
Developing an animal model of a disease can play an important role in both helping researchers to better understand that disease, as well as identifying and testing potential therapeutics. Animal…
Jason Tolson age 30 of Yorkshire, UK had not been diagnosed when he first began to have symptoms in May 2022. Jason began to experience muscle and joint pain…
Currently, there are a number of therapies which can be used to treat individuals with dermatomyositis: corticosteroids, immunosuppressive agents, intravenous immune globulin (IVIG). Typically, corticosteroids are considered a first-line treatment,…
One of the complications of COVID-19 is juvenile dermatomyositis (JDM), a connective tissue disease. In the Children's Medical Center in Iran, researchers documented that from Feb of 2020 to Feb…
According to a story from dailymail.co.uk, 59 year old Marcia Ferguson-Roa recently died only a few weeks after unusual symptoms, such as fatigue and ulcers on her head, began to…
Caroline is the adorable three-year-old daughter of Kevin and Kelly Brennan Culver, and she was diagnosed with juvenile dermatomyositis (JDM) about a year ago. This means that she requires an…
This year, the American College of Rheumatology (ACR) held their Convergence 2020 meeting virtually from November 5-9, with additional poster presentations on November 10 and 21. According to a…
According to a story from Biotech 365, the biotechology company Kezar Life Sciences, Inc. recently announced that its experimental therapy KZR-616 has earned Orphan Drug designations from the US Food…
Corbus Pharmaceuticals has just announced that participant enrollment for their Phase 3 trial of lenabasum for dermatomyositis has been completed. Dermatomyositis Dermatomyositis (DM) is a rare autoimmune disease. It can…
According to a story from GlobeNewswire, the drug development company Corbus Pharmaceuticals Holdings, Inc., has recently announced that it has completed its enrollment of patients for an upcoming phase 3…
A team of researchers recently evaluated a new biomarker in interstitial lung disease to see whether or not it could predict disease severity and ultimately mortality. The Biomarker Surfactant protein…
The medical field has seen many advancements over the past few decades. In particular, treatment for rheumatic diseases has greatly improved. However, states Healio, this is not reflected in patient…
Myositis Myositis is an autoimmune disease that leads to muscle damage. Patients live with chronic disability due to the symptoms of this rare condition. These include skin rashes, pain, weakness, fatigue,…
This year, because of COVID-19, many healthcare-related events and symposiums have been moved online. However, that doesn't mean that the insights are any less helpful! In the virtual ACR…
According to CNBC, there is a shortage across the country of a very important medication: hydroxychloroquine. This is somewhat unsurprising. After all, the Trump administration has been vocal about the…
Lisa Christopher-Stine is the Director of the Myositis Center at Johns Hopkins. She recently shared her biggest tips for patient care and some updates from the field, hoping to change…
Dermatomyositis (DM) is a disease which causes muscle weakness and rashes on the skin. Immunosuppressive drugs are a common treatment prescribed for the condition. Patients may also be given methotrexate, rituximab,…
Morgan's story Morgan Gleason is a 20-year-old living with Juvenile Dermatomyositis. It's a rare autoimmune condition causing weak muscles and rashes in addition to other symptoms. As a result of her…
New data has been released about the effects of lenabasum, an experimental drug, on patients with systemic sclerosis and dermatomyositis. Corbus, who are developing lenabasum, are planning to present the…
Corbus Pharmaceuticals have announced that they will go ahead with a Phase 3 study investigating the drug lenabasum as a potential treatment for dermatomyositis. For more information, you can view…
The 2018 Annual Patient Conference This conference will be an opportunity for patients, their families, and caregivers to learn the latest in research for various forms of myositis, such…
The US Food and Drug Administration has awarded Orphan Drug Designation to the drug lenabasum as a treatment for dermatomyositis. The use of lenabasum for treating this condition, and others,…
According to a story from globenewswire.com, the biopharmaceutical company Idera Pharmaceuticals recently released the data from its Phase 2 trial for IMO-8400, an investigational product in development for the treatment…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
